COMMUNIQUÉS West-GlobeNewswire
-
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
04/08/2026 -
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026
04/08/2026 -
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
04/08/2026 -
LeMaitre Q2 2026 Financial Results
04/08/2026 -
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
04/08/2026 -
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
04/08/2026 -
Sienna Reports Second Quarter 2026 Financial Results and Forms Redevelopment Joint Venture with Fiera Infrastructure
04/08/2026 -
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
04/08/2026 -
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026 -
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/08/2026 -
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
04/08/2026 -
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook
04/08/2026 -
ClinNEXUS Appoints John Stamatopoulos to New Position of Chief Growth Officer
04/08/2026 -
Beacon Behavioral Partners Expands National Footprint with First Georgia Partnership
04/08/2026 -
Carbonium Core Reports Rare Earth and Critical Mineral Content in Initial Sample Assay
04/08/2026 -
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
04/08/2026 -
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
04/08/2026 -
Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
04/08/2026 -
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
04/08/2026
Pages